- Home
- KLTOW vs CME Comparison
KLTOW vs CME Comparison
Compare KLTOW & CME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLTOW | CME |
|---|---|---|
| Founded | N/A | 1898 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 98.5B |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | KLTOW | CME |
|---|---|---|
| Price | $0.13 | $269.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $285.33 |
| AVG Volume (30 Days) | N/A | ★ 2.0M |
| Earning Date | N/A | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | N/A | ★ 8.52 |
| EPS | N/A | ★ 10.32 |
| Revenue | N/A | ★ $6,385,200,000.00 |
| Revenue This Year | N/A | $6.91 |
| Revenue Next Year | N/A | $4.98 |
| P/E Ratio | ★ N/A | $26.07 |
| Revenue Growth | N/A | ★ 5.81 |
| 52 Week Low | N/A | $224.62 |
| 52 Week High | N/A | $290.79 |
Technical Indicators
Market Signals| Indicator | KLTOW | CME |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 45.24 |
| Support Level | $0.09 | $264.80 |
| Resistance Level | $0.14 | $276.51 |
| Average True Range (ATR) | 0.02 | 4.92 |
| MACD | -0.00 | -0.62 |
| Stochastic Oscillator | 60.14 | 30.91 |
Price Performance
Historical ComparisonAbout KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About CME CME Group Inc.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.